Ivonescimab for advanced nasopharyngeal cancer after immunotherapy
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new drug called ivonescimab in patients whose nasopharyngeal cancer (a type of head and neck cancer) has spread or come back after previous chemotherapy and immunotherapy failed to stop it. The drug works by helping your immune system fight the cancer in a different way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with EBV-positive nasopharyngeal carcinoma (a virus-related form of this cancer)
- Your cancer has spread to other parts of your body or come back after treatment, and cannot be cured by surgery or radiation alone
- You have already received at least one prior treatment regimen that included platinum-based chemotherapy and anti-PD1 immunotherapy, and your cancer progressed despite this
- Your cancer can be measured on imaging scans using standard response criteria
- You are in good enough overall health to tolerate this experimental treatment (ECOG performance status 0 or 1)
- Your blood work and organ function tests show adequate kidney, liver, and bone marrow function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding ivonescimab, an immunotherapy drug, to standard chemoradiation for a type of nasopharyngeal cancer that has a higher risk of coming back. It aims to see if this combination can improve outcomes for patients with stage T3N2 or stage III disease.
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests two drugs—scipibaimab and tislelizumab—given together for people with nasopharyngeal cancer that has not responded to first-line platinum chemotherapy and a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.